Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy for muscle-invasive bladder cancer
NL-OMON59072Phase 4Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in bladder cancer and transitional cell carcinoma (TCC) comparing Pembrolizumab + chemoradiotherapy with Placebo + chemoradiotherapy (2 arms). Primary endpoint: Bladder Intact Event-Free Survival. Started Jul 2020; status: active, not recruiting.
02
Drugs
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON59072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59072.